US 12,153,054 B2
Method for isolating cell nuclei having enhanced antigenicity from fixed cells or FFPE tissue section, and antigen activator and kit therefor
Natsuki Sato, Tokyo (JP); Mika Kuroiwa, Tokyo (JP); Masatoshi Nakatsuji, Kawasaki (JP); and Hideki Ishihara, Tokyo (JP)
Assigned to NITTO BOSEKI CO., LTD., Fukushima (JP)
Appl. No. 16/975,930
Filed by NITTO BOSEKI CO., LTD., Fukushima (JP)
PCT Filed Feb. 28, 2019, PCT No. PCT/JP2019/007757
§ 371(c)(1), (2) Date Aug. 26, 2020,
PCT Pub. No. WO2019/168085, PCT Pub. Date Sep. 6, 2019.
Claims priority of application No. 2018-035696 (JP), filed on Feb. 28, 2018.
Prior Publication US 2020/0408770 A1, Dec. 31, 2020
Int. Cl. G01N 33/68 (2006.01); C12Q 1/6886 (2018.01); G01N 1/30 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/6875 (2013.01) [G01N 1/30 (2013.01); G01N 33/57496 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/435 (2013.01); G01N 2333/47 (2013.01); G01N 2333/4742 (2013.01); G01N 2333/723 (2013.01); G01N 2800/52 (2013.01)] 17 Claims
 
1. A method of activating Ki-67 in a population of fixed cells or a fixed tissue comprising pretreating the fixed cells or the fixed tissue with a hydrolase, which does not recognize or cleave the peptide of SEQ ID NO: 2;
wherein the pretreating occurs after the fixation of cells or tissue.